Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27678662 | 0.89 | HTR1A (0.44) | ADRA2AADRA2BADRA2CHTR1ASLC6A2 | |
| SCHEMBL6013570 | 0.85 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CHTR1ANISCH | |
| SCHEMBL5412735 | 0.83 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CSLC6A2SLC6A4 | |
| SCHEMBL11099859 | 0.82 | SLC6A2 (0.41) | ADRA2AADRA2BADRA2CHTR1ASLC6A2 | |
| SCHEMBL8053597 | 0.82 | IRAK4 (0.44) | ADRA2AADRA2BADRA2CHTR1ASLC6A2 | |
| SCHEMBL14130989 | 0.82 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR1ASLC6A2 | |
| SCHEMBL28947631 | 0.82 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CHTR1ASLC6A2 | |
| SCHEMBL8053601 | 0.82 | IRAK4 (0.44) | ADRA2AADRA2BADRA2CHTR1ASLC6A2 | |
| SCHEMBL3842137 | 0.82 | TAAR1 (0.63) | SLC6A2SLC6A4KCNH2IRAK4TAAR1 | |
| SCHEMBL11974049 | 0.82 | HTR1A (0.49) | ADRA2AADRA2BADRA2CHTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704118-B1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-12 | — | — | EP | disclosed |
| US-9765018-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765018-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160137595-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-19 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | ADRA2A 1023/4885ADRA2B 600/4885ADRA2C 944/4885 |
| US-20160137595-A1 | IDO INHIBITORS | IDO1, IDO2, TDO2 | ADRA2A 2795/4885ADRA2B 2636/4885ADRA2C 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.